Abstracts tagged "aquaporin"

Abstract Number: 143 • 2018 ACR/ARHP Annual Meeting
Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells
Ananta Paine¹, Maria de la Luz Garcia-Hernandez², Benjamin D. Korman², Judilyn Duculan³, Mayte Suarez-Farinas⁴, James G. Krueger³ and Christopher T. Ritchlin², ¹Department of Medicine, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ²Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ³Laboratory for Investigative Dermatology, Rockefeller University, New York City, New York, USA, New York City, NY, ⁴Icahn School of Medicine at Mount Sinai, New York City, New York, USA, New York City, NY
Background/Purpose: Th17, a subset of CD4+ helper T cells, provides protection against pathogens and malignancies, but also promotes immune-mediated-inflammation in a range of disorders including…
Abstract Number: 112 • 2017 Pediatric Rheumatology Symposium
Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder
Sabrina Gmuca¹, Amy T. Waldman², Pamela F. Weiss³ and Jeffrey S. Gerber², ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: First-line use of rituximab for neuromyelitis optica spectrum disorder (NMOSD) is common but the benefits of early immunosuppression remain unclear. We aimed to determine…
Abstract Number: 1348 • 2016 ACR/ARHP Annual Meeting
Neuromyelitis Optica: Patient Characteristics and Treatment Patterns Among Rheumatologists Versus Non-Rheumatologists
Sabrina Gmuca¹, Rui Xiao², Amy T. Waldman³, Jeffrey S. Gerber⁴ and Pamela F. Weiss⁵, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Pediatric Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neuromyelitis optica (NMO) is an immune-mediated inflammatory disorder of the central nervous system that has been associated with systemic autoimmunity often cared for by…
Abstract Number: 3229 • 2016 ACR/ARHP Annual Meeting
Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome
Hongen Yin¹, Lovika Kalra¹, Arif Karim¹, Zhennan Lai¹, Maria Guimaro¹, Lauren Aber¹, Bill Swaim¹, Sandra Afione¹, Alexandria Voigt², Cuong Nguyen³, Paul Yu⁴, Donald Bloch⁵ and John A. Chiorini¹, ¹Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ²Department of Pathology and Infectious Diseases, University of Florida, Gainesville, FL, ³Department of Pathology and Infectious Diseases, University of Florida, Bethesda, MD, ⁴Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Center for Immunology and Inflammatory Diseases and the Division of Rheumatology, Allergy, and Immunology of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Methods: Results: Elevated BMP6 was found in 63/80 (78.8%) of pSS patients examined in this study. In humans, ALK2 and ALK3 receptors…
Abstract Number: 1056 • 2015 ACR/ARHP Annual Meeting
Aquaporin Gene Therapy Corrects Bone Morphogenetic Protein 6 Associated Exocrine Gland Dysfunction in Mouse Model of Sjögren’s Syndrome
Hongen Yin¹, Zhennan Lai², Javier Cabrera-Perez³, Patricia Glenton⁴, Ankur Patel⁵, William Swaim⁵, Changyu Zheng⁵, Maria Guimaro⁵, Sandra Afione⁶, Cuong Nguyen⁵, Fred Nyberg⁷ and John A. Chiorini², ¹NIDCR, NIH, Bethesda, MD, ²Mptb, NIH/NIDCR, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Bethesda, MD, ⁴Department of Pathology and Infectious Diseases, University of Florida, Gaineville, FL, ⁵Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁶National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁷Department of Pharmaceutical Bioscience, Division of Biological Research on Drug Dependence, Uppsala University, Uppsala, MD, Sweden
Background/Purpose: Loss of secretory epithelial function is a hallmark of primary Sjögren’s syndrome (pSS). Previously we reported that bone morphogenetic protein 6 (BMP-6) inhibits cell volume…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].